On December 15, 2023, W. Bryan Hubbard was asked to resign as Chairman and Executive Director of the Kentucky Opioid Abatement Advisory Commission, a move that effectively halted the proposed Kentucky Ibogaine Initiative. The initiative aimed to launch what would have been the first clinical trial in the United States studying ibogaine as a treatment for opioid addiction and traumatic brain injury. Its sudden cancellation raised questions about the political, institutional, and financial pressures surrounding the proposal.
In response, Reveille Advisors conducted a pro bono open-source intelligence (OSINT) investigation examining the network of policymakers, institutions, researchers, donors, and industry stakeholders connected to the opposition. The research reviewed public records, campaign contributions, and professional affiliations to better understand the broader landscape surrounding the decision and the competing interests influencing the debate over ibogaine research in Kentucky.